Lin Shao-Lee's Form 4 filing
Cue Biopharma, Inc. (CUE) · filed Jul 10, 2026
- Accession no.
- 0001725092-26-000006
- Filed
- Jul 10, 2026, 7:32 PM ET
- Trade date
- Jul 9, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lin Shao-LeeCIK 0001725092 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Common Stock | AGrant or awardAcquired | +327,537 | $0.00 | $0 | 655,074 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Common Stock | AGrant or awardAcquired | +327,537 | $0.00 | $0 | 327,537 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.